Equity Overview
Price & Market Data
Price: $9.36
Daily Change: +$0.27 / 2.88%
Daily Range: $9.30 - $9.36
Market Cap: $481,879,936
Daily Volume: 870
Performance Metrics
1 Week: 5.94%
1 Month: -2.15%
3 Months: 78.24%
6 Months: 341.3%
1 Year: 502.0%
YTD: 73.80%
Company Details
Employees: 21
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.